Research Article
Urine Monocyte Chemoattractant Protein-1 and Lupus Nephritis Disease Activity: Preliminary Report of a Prospective Longitudinal Study
Table 5
Follow-up characteristics of the patient subgroup with LN active at baseline.
| | Parameters | Baseline | 2 months | 4 months | | Active LN (A) | A, | A, | A, | | Inactive LN (IA) | | IA, | IA, |
| | Systolic blood pressure | 128 ± 13.16 | 131.69 ± 12.62 | 130.23 ± 12.51 | | (mmHg) | | 121.86 ± 11.73 | 123.33 ± 11.87 | | Intergroup p value | | 0.01 | 0.01 |
| | Diastolic blood pressure | 77.80 ± 10.31 | 80.73 ± 10.76 | 81.15 ± 7.86 | | (mmHg) | | 72.73 ± 8.25 | 73.14 ± 9.01 | | Intergroup p value | | 0.03 | 0.77 |
| | Serum albumin | 37.78 ± 5.54 | 37.60 ± 5.02 | 36.92 ± 2.53 | | (35–50 g/L) | | 40.93 ± 2.54 | 40.66 ± 3.74 | | Intergroup p value | | 0.01 | 0.01 |
| | Serum creatinine | 69 (IQR 33–252) | 81.97 (IQR 40–244) | 86 (IQR 48–224) | | (44–80 mol/L) | | 67 (IQR 44–139) | 62 (IQR 41–143) | | Intergroup p value | | 0.43 | 0.01 |
| | eGFR | 93.61 ± 46.01 | 88.56 ± 40.88 | 71.15 ± 29.20 | | (60 mL/min/1.73 m2) | | 97.93 ± 31.81 | 99 ± 38.15 | | Intergroup p value | | 0.28 | 0.01 |
| | ESR | 38.5 (IQR 21–91) | 45 (IQR 22–92) | 32 (IQR 8–105) | |
(mm/hr) | | 55 (IQR 10–103) | 36.50 (IQR 1–70) | | Intergroup p value | | 0.48 | 0.78 |
| | Anti-dsDNA Ab titers | 35.18 (IQR 1.73–195.97) | 38.59 (IQR 0.74–267.61) | 13.75 (IQR 2.11–175.22) | | (<30 IU) | | 13.82 (IQR 1.54–135.29) | 41.53 (IQR 2.07–252.85) | | Intergroup p value | | 0.94 | 0.82 |
| | Serum C3 | 100.5 ± 36.39 | 96.44 ± 32.54 | 106.06 ± 39.29 | | (79–152 mg/dL) | | 113 ± 43.05 | 98.25 ± 21.99 | | Intergroup p value | | 0.43 | 0.50 |
| | Serum C4 | 21.46 ± 12.82 | 20.08 ± 10.12 | 22.15 ± 19.90 | | (16–38 mg/dL) | | 28.52 ± 16 | 22.93 ± 11.77 | | Intergroup p value | | 0.20 | 0.31 |
| | Proteinuria (uPCI) | 110 (IQR 10–510) | 120 (IQR 10–480) | 110 (IQR 10–510) | | (<20 mg/mmol creatinine) | | 30 (IQR 10–50) | 40 (IQR 10–50) | | Intergroup p value | | <0.001 | <0.001 |
| | Urinary leucocytes/HPF ×106/L | 0 (IQR 0–20) | 0 (IQR 0–20) | 0 (IQR 0–20) | | | | 0 (IQR 0–10) | 0 (IQR 0–5) | | Intergroup p value | | 0.31 | 0.009 |
| | Urinary RBC/HPF ×106/L | 0 (IQR 0–10) | 0 (IQR 0–20) | 0 (IQR 0–50) | | | | 0 (IQR 0–5) | 0 (IQR 0–20) | | Intergroup p value | | 0.29 | 0.23 |
| | uMCP-1 | 9,317 (IQR 548–40,170) | 5,031 (IQR 1,953.79–18,408) | 7,092.95 (IQR 1,208.69–17,070) | | (pg/mg creatinine) | | 2,955 (IQR 0–12,920) | 2,202.16 (IQR 0–10,573) | | Intergroup p value | | <0.001 | 0.001 |
| | SLEDAI-2K | 8 (IQR 0–18) | 6 (IQR 0–18) | 8 (IQR 4–16) | | (global: 0–105) | | 0 (IQR 0–12) | 2 (IQR 0–12) | | Intergroup p value | | <0.001 | <0.001 |
| | SLEDAI-2K | 4 (IQR 0–16) | 4 (IQR 0–12) | 4 (IQR 4–16) | | (renal: 0–16) | | 0 (IQR 0–8) | 0 (IQR 0–12) | | Intergroup p value | | <0.001 | <0.001 |
| | SLEDAI-2K | 4 (IQR 0–12) | 2 (IQR 0–10) | 4 (IQR 0–8) | | (extrarenal: 0–89) | | 0 (IQR 0–8) | 2 (IQR 0–4) | | Intergroup p value | | 0.10 | 0.65 |
|
|
